Yang Zhang

Prof. Dr. Yang Zhang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
WSWenjuan Shen
Wenjuan Shen
YQYangfan Qu
Yangfan Qu
HJHuan Jiang
Huan Jiang
HWHongwei Wang
Hongwei Wang
YPYujia Pan
Yujia Pan
YZYang Zhang
Yang Zhang
Background: Polycystic ovary syndrome (PCOS) is a multi-factorial heterogeneous syndrome that has both adverse reproductive and metabolic implications for affected women and its management is a challenging clinical problem. Curcumin, as a phenolic compound with potent anti-inflammatory and antioxidant properties exerting positive effects on the lipid profile and insulin resistance, appears to be a valuable treatment regimen for patients with PCOS.Objective: This study aimed to evaluate the efficacy and safety of curcumin in the treatment of PCOS.Methods: Chinese databases (Chinese National Knowledge Infrastructure, China Biology Medicine Databases, VIP database, Wanfang Database, and Chinese Clinical Trial Registry) and English databases (PubMed, Web of Science, Embase, Cochrane Library, Scopus and Clinical trials) were thoroughly investigated through screening randomized controlled trials on curcumin in PCOS published from the date of inception to May 2022. Standardized data search and abstraction were conducted following the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement. Quantitative and qualitative analyses were performed. Heterogeneity was assessed using I2 statistics.Results: A total of 447 patients from seven randomized controlled trials were included in the meta‐analysis. Results showed that the ingestion of curcumin decreased body mass index (WMD -0.267, 95% CI -0.450 to -0.084, P = 0.004, I2 = 0.0%), fasting plasma glucose (WMD -3.618, 95% CI -5.165 to -2.071, P < 0.001, I2 = 20.4%), insulin (WMD -1.834, 95% CI -2.701 to -0.968, P < 0.001, I2 = 8.4%), homeostatic model assessment for insulin resistance (WMD -0.565, 95% CI -0.779 to -0.351, P < 0.001, I2 = 0.0%), total cholesterol (WMD -15.591, 95% CI -27.908 to -3.273, P = 0.013, I2 = 68.9%), C-reactive protein (WMD -0.785, 95% CI -1.553 to -0.017, P = 0.045, I2 = 23.9%), and increased the quantitative insulin sensitivity check index (WMD 0.011, 95% CI 0.005 to 0.017, P = 0.001, I2 = 39.6%). As for safety, the treatment group did not cause significant adverse reactions than that in the control group.Conclusion: In light of presented findings, curcumin has beneficial effects on serum markers of inflammation, weight loss and glucose and lipid metabolism in patients with PCOS. The incidence of adverse reactions does not increase with the application of curcumin. However, a larger, more definitive study is needed to further investigate these results.Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022332394.

26 February 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
WSWenjuan Shen
Wenjuan Shen
BJBao Jin
Bao Jin
YPYujia Pan
Yujia Pan
YHYanhua Han
Yanhua Han
TYTianjiao You
Tianjiao You
YZYang Zhang
Yang Zhang
Polycystic ovary syndrome (PCOS) is a touchy clinical and public health problem worldwide, which adversely affects women’s health and health-related comorbidities for lifetime, and represents a tremendous burden for both the family of the patient and for society. According to the diagnostic criteria used and the population studied, the prevalence rate of PCOS is between 6% and 21%. However, current conventional modern medicines for PCOS are only moderately effective at controlling the signs and symptoms, while they are not thoroughly able to prevent complications. Therefore, many patients have turned to complementary and alternative medical (CAM) treatments. CAM use is wide spread among patients with PCOS, and more than 70% of patients use CAM at one point during their diseases. The patients’ primary motivations include dissatisfaction with available medications, perceive higher risk of drug side effects and crushing health burden and economic costs, desire for symptom relief, pursuit of shortening the course of disease, and the belief that CAM therapy is in accordance with the patients’ values and beliefs. At present, several CAM methods have been used in women with PCOS, which has achieved obvious effects. However, biologically plausible mechanisms of the action of traditional Chinese medicine- (TCM-) associated CAM for PCOS have not been systematically reviewed. This review briefly summarizes the current progress of the impact of herbal medicine on the outcomes of PCOS and introduces the mechanisms.

9 October 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SNSiying Niu
Siying Niu
YZYang Zhang
Yang Zhang
The development of ulcerative colitis (UC), a highly prevalent inflammatory bowel disease worldwide, is closely related to the key regulatory role of the PI3K/Akt signaling pathway. Although the use of Western drugs is the standard clinical treatment, the problems of drug resistance, side effects, and efficacy limitations are prominent. In contrast, Traditional Chinese Medicine (TCM), with the advantages of multi-target regulation and low toxicity and side effects, demonstrates the potential for and offers highly effective treatment. This paper systematically analyzes the mechanism of the PI3K/Akt pathway in UC. It focuses on how TCM metabolites, extracts, and formulas regulate inflammatory responses, oxidative stress, autophagy and apoptosis, intestinal barrier function, and gut microbiota homeostasis by targeting the pathway, which together can achieve the goal of alleviating the symptoms of UC. Our goal is to provide new insights into the prevention and treatment of UC and to contribute to the standardization of TCM.

1 April 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
HSHeyuan Sun
Heyuan Sun
TLTong Liu
Tong Liu
ZWZijian Wang
Zijian Wang
WSWenjuan Shen
Wenjuan Shen
XYXingxing Yuan
Xingxing Yuan
YZYang Zhang
Yang Zhang
Chronic liver disease is a major global health concern, posing significant challenges due to its asymptomatic progression and the limitations of conventional treatments. Effective therapeutic strategies remain a pressing need. Curcumin, a natural polyphenolic compound derived from turmeric rhizomes, has demonstrated diverse pharmacological properties. Beyond its well-known antioxidant activity, curcumin exhibits anti-inflammatory, antiviral, and anti-fibrotic effects, along with the ability to regulate cellular autophagy and apoptosis. Recent studies suggest its potential to inhibit the progression of chronic liver disease through multiple molecular pathways. This review summarizes the latest research on curcumin’s therapeutic effects in chronic liver disease, focusing on its mechanisms of action and clinical relevance. By integrating findings from experimental and clinical studies, we aim to provide novel insights into curcumin as a promising therapeutic candidate for liver disease management.

8 December 2023 in BMC Public Health
Verified
Journal Article
Open access
PDF file
RLRunyou Liu
Runyou Liu
YZYang Zhang
Yang Zhang
JMJingxuan Ma
Jingxuan Ma
HWHongjian Wang
Hongjian Wang
YLYajia Lan
Yajia Lan
XTXuefeng Tang
Xuefeng Tang
Background: A major shift in the “dynamic zero-COVID” policy was announced by China’s National Health Commission on December 7, 2022, and the subsequent immediate large-scale outbreak of SARS-CoV-2 infections in the entire country has caused worldwide concern. This observational cross-sectional study aimed to describe the epidemiological characteristics of this outbreak in Sichuan, China. Methods: All data were self-reported online by volunteers. We described the epidemic by characterizing the infection, symptoms, clinical duration, severity, spatiotemporal clustering, and dynamic features of the disease. Prevalence ratio (PR), Odds ratios (ORs) and adjusted ORs were calculated to analyze the associations between risk factors and infection and the associations of risk factors with clinical severity using log-binomial and multivariable logistic regression models; 95% confidence intervals (CIs) and Wald test results were reported. The prevalence rates and clinical severity among different subgroups were compared using the Chi-square and trend Chi-square tests. Results: Between January 6 and 12, 2023, 138,073 volunteers were enrolled in this survey, and 102,645 were infected with COVID-19, holding a prevalence rate of 74.34%; the proportion of asymptomatic infections was 1.58%. Log-binomial regression revealed that the risk of infection increased among those living in urban areas. Multivariable logistic regression analysis showed that female sex, chronic diseases, older age and the fewer doses of vaccine received were associated with an increased risk of severe clinical outcomes after infection. We estimated the mean reproduction number during this pandemic was 1.83. The highest time-dependent reproduction number was 4.15; this number decreased below 1 after 11 days from December 7, 2022. Temporal trends revealed a single peak curve with a plateau pattern of incidence during the outbreak, whereas spatiotemporal clustering analysis showed that the onset in 21 cities in the Sichuan province had four-wave peaks. Conclusions: The peak of the first wave of Omicron infection in Sichuan Province had passed and could be considered a snapshot of China under the new control strategy. There were significant increases in the risk of severe clinical outcomes after infection among females, with chronic diseases, and the elderly. The vaccines have been effective in reducing poor clinical outcomes.

13 December 2021 in Frontiers in Endocrinology
Verified
Journal Article
Open access
WSWenjuan Shen
Wenjuan Shen
YPYujia Pan
Yujia Pan
BJBao Jin
Bao Jin
ZZZongyu Zhang
Zongyu Zhang
TYTianjiao You
Tianjiao You
YZYang Zhang
Yang Zhang
Objective: Our aim was to conduct a systematic review and meta-analysis to assess the effectiveness and safety of tea supplements for patients with polycystic ovary syndrome (PCOS).Methods: We conducted searches of the published literature in PubMed, EMBASE, Cochrane Library, Web of Science, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure (CNKI), VIP database, and Wanfang Database in 1985 to September 2021. Data from randomized controlled trials (RCTs) were obtained to assess the effects of tea versus placebo in women with PCOS. Weighted mean differences (WMDs) were pooled using a random-effects model or risks ratios (RRs) using a random-effects model.Results: Six RCTs (235 participants) were included in our systematic review. Tea supplements as adjuvant therapy led to greater improvement in body weight (WMD −2.71, 95% CI −4.95 to −0.46, P = 0.02, I2 = 0%), fasting blood glucose (FBG: WMD −0.40, 95% CI −0.59 to −0.20, P < 0.0001, I2 = 0%) and fasting insulin (FINS: WMD −3.40, 95% CI −4.76 to −2.03, P < 0.00001, I2 = 0%) when compared with placebo. There were no significant differences of body mass index, waist circumference, hip circumference, waist-to-hip ratio (WHR), body fat rate, total testosterone, free testosterone (FT), dehydroepiandrosterone, luteinizing hormone or follicular-stimulating hormone (FSH) between the two groups. In addition, subgroup analysis suggested that green tea was effective on body weight, FINS, FBG, FT, and FSH, and herbal tea can also reduce FT levels, tea supplements had a significant impact on FBG and FSH in trials with intervention duration ≥ 3 months, and intervention lasting less than 3 months can improve FINS. Tea had significant effect on reducing WHR, FBG and FSH in Asian PCOS patients, but not in Caucasians. And there was no statistically significant effect of tea on weight and FINS in Asians, but it was effective for Caucasian participants. Compared with placebo, tea supplements did not cause significant adverse reactions (RR 1.45, 95% CI 0.30 to 6.90, P = 0.65, I2 = 0%).Conclusion: This meta-analysis suggests that consumption of tea supplementation in women with PCOS could significantly decrease the levels of FBG and FINS as well as reduce body weight. Especially green tea, not only has the above effects, but also has a significant effect on improving a variety of reproductive hormone indexes. Furthermore, tea supplementation is a relatively safe therapy for PCOS patients. Systematic Review Registration: PROSPERO https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=212755, identifier CRD42021249196.